Previous treatment with talazoparib
Known hypersensitivity to any of the components of talazoparib
Prior treatment with talazoparib
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of talazoparib
Patients who have had prior BMN673 (talazoparib) therapy
Known hypersensitivity to any of the components of talazoparib
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Female patients may not be breastfeeding at the first dose of talazoparib and must not breastfeed during study participation through 45 days after the last dose of talazoparib.